Disease-free survival
Fig. 2. · Panel A
Panel A 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xiaowen Liu, Jiejie Jin, Menglong Zhou, Ye Zhou, Hong Cai, Hua Huang, Min Yan, Zhongyin Yang, Runhua Feng, Qi Lu, Hao Ding, Hongtao Xu, Xuexiao Liu, Guichao Li, Hui Zhu, Weiqi Sheng, Xiujiang Yang, Zhen Zhang, Yanong Wang
Cancer Commun (Lond) 46 0006
Background: The prognostic superiority of preoperative chemoradiotherapy (pre-CRT) over preoperative chemotherapy (pre-CT) in patients with locally advanced gastric cancer remains controversial. Herein, we evaluated the efficacy and safety of pre-CRT relative to those of pre-CT in this cohort. Methods: This open-label, phase III, randomized controlled trial was conducted at 4 medical centers in China. Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma were randomly assigned (1:1) to receive either 3 cycles of oxaliplatin and S-1 (SOX), followed by surgery and 3 postoperative cycles of SOX (pre-CT), or 1 cycle of SOX, followed by concurrent chemoradiotherapy, a second cycle of SOX, surgery, and 3 postoperative cycles of SOX (pre-CRT). The primary endpoint was 3-year disease-free survival (DFS). Secondary endpoints included 3-year overall survival (OS), R0 resection rate, pathological complete response (pCR) rate, treatment-related toxicity, and postoperative complications. Results: Due to premature trial termination, only 204 patients were enrolled, and an efficacy analysis was conducted on 194 eligible patients. The baseline characteristics were well balanced between the 2 groups. The DFS and OS were indistinguishable between the 2 groups. The 3-year DFS rates were 53.6% in the pre-CRT group and 53.9% in the pre-CT group [hazard ratio (HR), 1.02; 95% confidence interval (CI), 0.70 to 1.50; log-rank P = 0.913]. The 3-year OS rates were 62.8% in the pre-CRT group and 60.5% in the pre-CT group (HR, 0.97; 95% CI, 0.63 to 1.47; log-rank P = 0.874). The R0 resection rates were 81.0% and 74.5% in the pre-CRT and pre-CT groups, respectively. Additionally, the pCR rate was higher in the pre-CRT group (12.0%) than in the pre-CT group (2.1%). Treatment-related toxic effects were comparable between the 2 groups. Conclusion: This trial did not demonstrate a survival advantage for pre-CRT over pre-CT in patients with locally advanced gastric or gastroesophageal adenocarcinoma.
2 个 Figure · 4 个 KM 面板
Fig. 2. Kaplan–Meier estimates of survival in the modified intention-to-treat cohort. (A) The disease-free survival curves. (B) The overall survival curves. Pre-CT, preoperative chemotherapy; Pre-CRT, preoperative chemoradiotherapy; HR, hazard ratio; 95% CI, 95% confidence interval; No., number.
Fig. 2. · Panel A
Panel A 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2. · Panel B
Panel B 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3. Kaplan–Meier estimates of survival in the R0 resection population. (A) The disease-free survival curves. (B) The overall survival curves. Pre-CT, preoperative chemotherapy; Pre-CRT, preoperative chemoradiotherapy; HR, hazard ratio; 95% CI, 95% confidence interval; No., number.
这些图片未产生 KM 曲线结果,不在主页面重复展示。